Esperion shareholders approve merger with Essence Parent Inc.

Esperion Therapeutics, Inc.

Merger Agreement approved with 135,326,793 votes for, 22,750,628 against, 496,194 abstentions.
Advisory compensation proposal approved with 129,937,383 votes for, 22,283,787 against, 6,352,445 abstentions.
Quorum of 61.53% of outstanding shares represented at July 8, 2026 special meeting.
MergerCo will merge into Esperion, which will survive as wholly owned subsidiary of Parent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.